SNTS Description — Santarus Inc
Santarus is a biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician. As of Dec 31 2012, Co. the following products in the U.S. prescription pharmaceutical market: Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate), and Fenoglide (fenofibrate). Co.'s investigational drugs includes: Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV multi-matrix system, and SAN-300 (anti-VLA-1 antibody).